purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation opk earnings call period ending december image source motley fool opko health opk q earnings callfeb pm etcontents prepared remark question answer call participant prepared remark operatorgood day welcome opko health fourth quarter financial result conference call operator instruction please note event recorded would like turn conference yvonne briggs please go aheadyvonne briggs investor relation thank operator good afternoon yvonne briggs lha thank joining today call discus opko health financial result fourth quarter would like remind statement made call management statement historical fact considered forwardlooking subject risk uncertainty could materially affect company expected result forwardlooking statement include without limitation various risk described company sec filing including annual report form k year ended december subsequently filed sec report conference call contains timesensitive information accurate date live broadcast february except required law opko undertakes obligation revise update forwardlooking statement reflect event circumstance date callbefore begin let review format today call dr phillip frost chairman chief executive officer open call dr elia zerhouni vice chairman president provide overview opkos pharmaceutical business well bioreference health adam logal opkos cfo review company fourth quarter financial result open call question would like turn call dr frost phil frost chairman chief executive officer good afternoon thank joining u today year significant achievement opko expect continued progress ngenla longacting growth hormone therapy approved fda sale yous largest growth hormone market world pfizer global commercial partner launched ngenla market worldwide optimistic pfizers ability convert user weekly injection daily penetrate growing billion market modex made great stride last year particular executing strategy secure important collaboration advance multispecific biologics platform clinic collaboration provide nondilutive funding advance unique pipeline commercial realization specifically last march announced exclusive worldwide license collaboration agreement merck develop modexs nanoparticle vaccine candidate epsteinbarr virus received sizable upfront payment eligible milestone royalty payment september modex awarded contract biomedical advanced research development authority known barda develop novel multispecific antibody virus infectious disease deemed public health threat barda contract included initial payment develop multispecific antibody treat prevent covid additional funding may available develop multispecific antibody targeting viral pathogen influenza elia provide detail program sale rayaldee drug treat chronic kidney disease patient elevated parathyroid hormone low vitamin level grew last year expecting progress year gathering data indicate rayaldee may slow chronic kidney disease progression asking longtime enthusiasm onceweekly oxyntomodulin product treat type diabetes obesity remember completed successful phase trial achieving significant weight loss lowering serum cholesterol triglyceride lowered ac level delayed phase trial product appeared provided greater weight loss noting great commercial success product decided closer look polyethylene glycol peg added base peptide increase half life large bulky increased viscosity injection limited maximum dose administered related amount weight loss found substitute peg make molecule size similar market guarded optimism early stage preclinical evaluation product switching international business opko iberoamerica finetech eirgen well turning bioreference health team worked hard improve cost structure enhance revenue addition expense reduction effort bioreference aiming drive growth higher value segment new test larger customer better insurance reimbursement laserfocused returning segment profitability near term elia provide detail overview turn eliaselias zerhouni vice chairman president thank phil good afternoon everyone phil mentioned last year quite eventful operating segment opko health ngenla launch major global market mentioned phil progressing well believe drug wellpositioned significant growth nextgeneration longacting therapy administered week daily assisted easing burden especially pediatric market increase medication adherence ngenla annual growth anticipated excess part partnership pfizer opkos inaudible achieve additional million milestone payment associated approval adult indication growth hormone deficiency additional pediatric indication global registration strategy underway adult application pediatric indication currently phase clinical trial phil also mentioned success last year securing collaboration modex therapeutic barda merck recently barda secured initial million grant fund rd clinical evaluation phase study multispecific antibody known variant sarscov treatment well prevention covid remains particular drug especially immunocompromised patient additional funding million based upon achievement certain milestone first phase may available barda develop multispecific antibody targeting viral pathogen influenza part research program genebased delivery method multispecific antibody developed using mrna dna vector supplement body natural protein production process hopefully provide barda platform used quickly emerging platform addition announced collaboration merck develop mdx epsteinbarr virus multivalent nanoparticle vaccine received million upfront payment license vaccine potential million development commercial milestone scaled royalty global sale ranging singledigit doubledigit percentage program truly leverage modexs nanoparticlebased vaccine platform enables simultaneous immunization several major ebv protein case four major ebv protein platform potential fact address multiple antigen multiple viral disease market opportunity quite large epsteinbarr virus affect global adult population lifetime moreover cancer case annually caused ebv along association multiple sclerosis virus working merck ind clinical study expect phase clinical trial start later year round modex pipeline partnered nih develop antiviral multispecific antibody focused treatment prevention hiv success firstgeneration candidate phase trial moving forward potent nextgeneration tetraspecific antibody versus previous trispecific one believe unmet need therapy provide longacting protection treatment patient require option beyond small moleculebased therapy lastly immunooncology program focus hardtotreat solid tumor well liquid tumor leukemia lymphoma multispecific antibody candidate simultaneously target several tumor antigen enable better control immune system activation tetraspecific laser program treat solid tumor expected enter clinic first half year would like turn review diagnostics segment bioreference health transition year diagnostics division get closer turning corner profitability know implemented reach initiative reduce cost improve efficiency enhance productivity example reduced headcount headcount parallel driving growth various testing segment including highervalue specialty segment like oncology woman health urology primarily proprietary kscore test kscore test volume continued perform expect volume continue test included american urology association ncnn guideline early detection prostate cancer followup psa screening initial repeat biopsy risk stratification addition expect recent expansion insurance coverage continue bolster level year genpath continued launch innovative testing including expanded hematologic malignancy panel introducing several new test market sustain growth genpath oncology product advance made year example signed new account fourth quarter accession additional accession also signed major oncology group like virginia oncology group oncologist component u oncology started november summary bioreference health made great progress last year expect continue build achievement narrowed operating loss sequentially expense reduction revenue growth continue feel confident effort improve financial metric return segment profitability next year turn call adam logal discus fourth quarter financial result adamadam logal chief financial officer thank elia starting pharmaceutical segment revenue increased million fourth quarter million comparable period revenue product including international pharmaceutical business rayaldee increased million reflecting improvement number prescription overall net price revenue increased result gross profit share payment pfizer due global launch ngenla resulting million revenue quarter fourth quarter revenue includes catchup payment yous market related third quarter million mentioned last quarter yous launch occurred midaugust pfizer delayed reporting gross profit share amount result none included third quarter result cost expense million fourth quarter compared million period research development expense fourth quarter million compared million comparable period increase reflects activity modex development program partially offset decreased spending ngenla well rd tax credit irish activity resulting operating loss quarter ended december million million improvement operating loss million fourth quarter amortization expense related intangible asset million million fourth quarter respectively moving diagnostics segment reported revenue q million compared million period decline primarily reflects lower covid testing million well change estimated collection million partially offset increased testing volume cost expense increased million fourth quarter million period operating loss diagnostics segment included change estimated collection well approximately million nonrecurring cost related employee severance retention program associated effort return profitability depreciation amortization expense million million period respectively turning consolidated financial result fourth quarter reported operating loss million compared operating loss million quarter net loss fourth quarter million per share compare net loss million per share quarter reflecting lower noncash marktomarket loss related investment genedx would like briefly comment balance sheet recently completed refinancing convertible debt december two convertible debt issuance set mature early note held number institution note primarily held dr frost dr hsiao longterm investor opko consultation advisor jp morgan chose issue new fiveyear note reducing coupon interest rate took advantage strong demand institutional investor raise total million used proceeds buy back outstanding note million share common stock added approximately million cash balance sheet note holder exchanged principal accrued interest approximately million note identical financial term note holder refinancing strengthened balance sheet reduced number share outstanding provided company additional cash fund ongoing development activity offering oversubscribed brought impressive group new prominent investor opko anticipate receipt additional nondilutive cash payment existing collaboration merck barda potential transaction year progress look ahead providing following financial guidance following assumption pharmaceutical segment number factor impact gross profit share payment pfizer including revenue product sale genotropin ngenla global sale genotropin reported pfizer million pfizer separately reported sale ngenla however observed consistent prescription growth globally ngenla reported iqvia symphony full year estimate gross profit share million million although anticipate number scenario may impact sale genotropin ngenla globally assume stable foreign exchange rate ex yous pharmaceutical business allow continued profitable growth rd expense first quarter reflect higher activity related modex program including cmc effort related initiation first immunooncology clinical trial increased activity partially funded barda agreement partially offset lower rd cost related wind clinical operation ongoing openlabel pediatric extension study ngenla expect substantially complete end first quarter diagnostics segment elia outlined diligently working align business achieve cash flow breakeven middle profitability end year work includes consolidating geographic footprint rationalizing test offering result expect client mix improve cost structure appropriately support goforward strategy transition phase expect consistent core testing volume slight increase average per patient collection amount due revenue cycle management initiative partially offset volume impact due several weather event occurred first quarter already considering nonrecurring cost may result restructuring activity expect cost expense decline sequentially million approximately million result expect following first quarter total revenue million million revenue service million million revenue product sale million million revenue million million inclusive estimated pfizer gross profit share payment million million expect first quarter cost expense million million including rd expense million million dependent timing certain cmc activity modex program depreciation amortization expense million concludes prepared remark thank attention operator let u open call question question answer operatoroperator instruction first question come jeffrey cohen ladenburgjeff cohen ladenburg thalmann company analyst guess first adam could recap financials regard instrument currently share count toward approximately would appropriate cash debt level whereupon estimating pro formaadam logal chief financial officer yes ended year million cash pro forma additional million would put u right million cash pro forma basis total convertible note million right million principal got share count right jeff cohen ladenburg thalmann company analyst ok perfect got could one discus little bit press release regard alibaba global platform china talk perhaps product planning offering would expect far status phil frost chairman chief executive officer product involved made irish company sorry spanish company primarily nutritional product animal appears large market china beginning much else say itjeff cohen ladenburg thalmann company analyst ok got lastly u could provide commentary ngenla daily going weekly learned pfizers learned perhaps versus anticipated far cost transference patient one new patient may look coming yearadam logal chief financial officer start jeff think seen market mature pfizer launched initially good steady growth conversion happening broadly think one competitor launching bit earlier yous market seen conversion happen similar seen globally expect continue accelerate pfizer enters market well novo eventually enters market longacting product conversion happening expect accelerate next monthsjeff cohen ladenburg thalmann company analyst ok perfect lastly rayaldee sound like expecting growth looked like q strong growth could identify u may coming either demographically geographically pricingwise expect thatadam logal chief financial officer charlies want go ahead take onecharlie bishop chief executive officer renal division yes happy seeing growth number reason rayaldee brand first obvious passing adverse effect pandemic slowed ability sale force get clinic promote brand also slowed ability patient get clinic get prescription seems abated beginning q last year addition sale force much adept moving product area business low copays would include medicaid sector includes lowincome subsidy medicare part patient also includes commercial patient zero copay main driver growth businessjeff cohen ladenburg thalmann company analyst ok got seems like nice trajectory post covid currently ok think usoperatorthe next question come maury raycroft jefferiesmaury raycroft jefferies analyst wondering talk timing next step ngenla label expansion adult setting additional pediatric indicationselias zerhouni vice chairman president yes quickly adult indication basically process pfizer obviously put application fda mentioned comment toward end phase pediatric indication timingwise probably end year beginning next year adult probably early next year pediatrics everything go wellmaury raycroft jefferies analyst got ok profit share pfizer wanted make sure heard correctly guidance million million right wondering detail provide profit share currently change ngenla take market share genotropin would peak profit share percent look likeadam logal chief financial officer sure maury way million million correct full year guide based information know today right pfizer separately forecast ngenla genotropin sale using internal model calculate anticipate franchise revenue globally apply various table come estimated calculation got conservatism built uncertainty daily portion genotropin modest growth rate would expect ngenla got million million right fourth quarter take third quarter catchup million gross profit share payment think modest growth forecasting gross profit share see math kind look like overall look peak look growth hormone franchise whole combination ngenla genotropin product peak think peak could think pfizer stated think total market potential ngenla substantial revenue stream estimated effective royalty rate mids franchise peak pretty substantial cash flow would expect see growth hit peakmaury raycroft jefferies analyst got helpful maybe last question oxyntomodulin could talk time line new formulation would clinical development path look like something going keep inhouse partner leadermed right programphil frost chairman chief executive officer think respect question early get back soon something definitive talk aboutoperatorthe next question come edward tenthoff piper sandleredward tenthoff piper sandler analyst two quick question may firstly high level respect ngenla versus genotropin difference pfizer pushing term marketing really land grab point going genotropin client converting basically trying get many account possible second question really phil high level bioreference diagnostic business return breakeven plan still keep part opko potentially monetize diagnostic segmentproducts ultimately see business pharma diagnostics going forwardphil frost chairman chief executive officer well know realize first foremost always best interest shareholder term creating value particular point time one approach seems advisable certainly consider seriously want specific right clear asset book moment losing money although optimistic turning around inherent value asset mindful assurededward tenthoff piper sandler analyst yes competition sort little bit marketing longacting weekly inaudibleadam logal chief financial officer yes obviously pfizer leading charge commercial effort think going successful near term alone market right think japanese market substantial market growth hormone space currently meaningful market share penetration continued growth number country done great job marketing throughout europe well forcing conversion suggesting conversion well yous market got access commercially strong number plan think wellpositioned team go ahead take substantial share yous well far going go think question pfizer answeroperatorthe next question come yi chen hc wainright coyi chen hc wainwright company analyst helloadam logal chief financial officer hey yi hear nowyi chen hc wainwright company analyst sorry regarding storefront alibaba talk potential market size opko target potential revenue contribution current economic environment could affect market prospect petphil frost chairman chief executive officer product line successful sold spanish unit manufacture product develop product done well beginning expand france matter fact every intention continue expand geographically approached company partnership alibaba thinking tremendous interest pet animal china product successful might willing let distribute alibaba china said getting launched early say much market size product sold alibaba waitandsee situationyi chen hc wainwright company analyst strictly animal health product right human product offered storefrontadam logal chief financial officer combination human health veterinary product eventually go platformyi chen hc wainwright company analyst right rightoperatorthis concludes questionandanswer session would like turn conference back dr phillip frost closing remarksphil frost chairman chief executive officer well would like certainly thank participating today session hope u report first quarter result thank youoperatoroperator signoff duration minutescall participantsyvonne briggs investor relationsphil frost chairman chief executive officerelias zerhouni vice chairman presidentadam logal chief financial officerjeff cohen ladenburg thalmann company analystcharlie bishop chief executive officer renal divisionmaury raycroft jefferies analystedward tenthoff piper sandler analystyi chen hc wainwright company analyst opk analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy